LY3650150

Phase 3Small molecule

Eli Lilly

LY3650150 is one of 65 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Chronic RhinosinusitisActive, not recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)Recruiting

Allergic RhinitisPhase 3

Active, not recruiting

Chronic RhinosinusitisPhase 3

Active, not recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)Phase 3

Recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Asmanex Hfa

PPerrigo Company

Phase 3

5 2

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 3

Elestat

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 4

Azelastine Hydrochloride

Bayer

Phase 3

2 5

REGN1908-1909

Regeneron

Phase 3

1 6

LY3650150

Eli Lilly

Phase 3

1 7

Asmanex

Novartis

Preclinical

12 8

Ismigen

LLallemand Pharma AG

Phase 3

1 9

Veramyst

Singulair

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)

NCT06338995

Q4 2028

Phase 3Recruiting

Allergic Rhinitis

NCT06339008

Clinical

Trials by Indication[1]

Allergic Rhinitis1 trial

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06339008·450 enrolled

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants With Chronic Rhinosinusitis With Nasal Polyps on Background Intranasal Corticosteroids

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT06338995·510 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LY3650150. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY3650150 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY3650150. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

LY3650150

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Trials by Indication[1]

Allergic Rhinitis1 trial

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

References

Drug Info

Quick Facts

Related News